Hologic Enters Into Agreements with Novation for Mammography and Bone Densitometry Systems

BEDFORD, Mass., Aug. 18, 2005 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women's health, today announced it has been awarded two three-year dual-source contracts with Novation, LLC, one of the nation's foremost healthcare group purchasing organizations. The first agreement covers the purchase and sale of Hologic's analog and digital mammography systems and the second covers Hologic's bone densitometry systems. The effective date for both of these agreements is September 1, 2005.

"We are pleased to continue our relationship with Novation and the member organizations it serves through this contract award," said Jack W. Cumming, Hologic's Chairman and Chief Executive Officer. "These agreements further confirm the leadership position that Hologic's products have achieved in the diagnostic imaging arena. We look forward to working with Novation to bring the benefits of our mammography and bone densitometry imaging systems to the patients served throughout its network of facilities."

About Novation

Based in Irving, Texas, Novation was established in January 1998 through a combination of the supply programs of VHA and UHC, two national health care alliances. Novation serves the purchasing needs of more than 2,500 members and affiliates of VHA and UHC. These organizations used Novation contracts to purchase more than $23 billion in supplies in 2004.

About Hologic

Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information visit

Forward Looking Disclaimer

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the relationship and anticipated benefits from Hologic's agreement with Novation, LLC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, the risk that Novation's participating hospitals may choose not to purchase Hologic's products; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, such as the ability to obtain FDA approval to market products developed, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for the technologies and products anticipated to be developed; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; the need to comply with especially high standards in the manufacture of medical products; technical innovations that could render the technology or products under development obsolete; competition; and reimbursement policies for the use of products, if and when developed. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.

   Glenn P. Muir                      Frances Crecco
   Executive Vice President & CFO     Director, Investor Relations
   Hologic, Inc.                      Hologic, Inc.
   (781) 999-7300                     (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300,
or Frances Crecco, Director, Investor Relations, +1-781-999-7377, both of
Hologic, Inc.

Web site: